Journal of Clinical Oncology, Vol 16, 3078-3081, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer

DH Lau, JJ Crowley, DR Gandara, MB Hazuka, KS Albain, B Leigh, WS Fletcher, KS Lanier, WL Keiser and RB Livingston
University of California Davis Cancer Center, Sacramento, USA.

PURPOSE: A phase II study was conducted by the Southwest Oncology Group (SWOG) to assess the efficacy and toxicity of concurrent carboplatin, etoposide, and thoracic radiation (XRT) in a defined population of poor- risk patients with stage III non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients with stage III NSCLC were eligible if they were excluded from cisplatin-based protocols because of poor pulmonary or renal function, history of congestive heart failure, hearing loss, peripheral neuropathy, or weight loss. Carboplatin 200 mg/m2 daily intravenously days 1, 3, 29, and 31 and etoposide 50 mg/m2 daily intravenously days 1 through 4 and 29 through 32 were administered. Beginning day 1, XRT was delivered at 1.8 to 2.0 Gy daily to a total dose of 61 Gy. RESULTS: Within a period of 1 year, 63 patients were registered and 60 were eligible. Patient characteristics were age 47 to 79 years, performance status 0 to 1 (82%) and 2 (18%), and stages IIIA (60%) and IIIB (40%) NSCLC. The most common grades 3 and 4 toxicities included leukopenia (50%), thrombocytopenia (23%), and esophagitis (15%). There were no treatment-related deaths. The overall confirmed response rate was 29%, and median overall survival was 13 months (95% confidence interval, 11 to 14 months). The 2-year survival rate was 21%. CONCLUSION: This chemoradiotherapy regimen is well tolerated in poor-risk patients and yields a median survival similar to that of good-risk patients who received cisplatin-based chemoradiotherapy. This chemoradiotherapy regimen will be compared with XRT alone in poor-risk patients with stage III NSCLC in a randomized phase III trial.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. M. Davies, K. Chansky, D. H.M. Lau, B. R. Leigh, L. E. Gaspar, G. R. Weiss, A. J. Wozniak, J. J. Crowley, and D. R. Gandara Phase II Study of Consolidation Paclitaxel After Concurrent Chemoradiation in Poor-Risk Stage III Non Small-Cell Lung Cancer: SWOG S9712 J. Clin. Oncol., November 20, 2006; 24(33): 5242 - 5246. [Abstract] [Full Text] [PDF]

				E. E. Vokes, J. Crawford, J. Bogart, M. A. Socinski, G. Clamon, and M. R. Green Concurrent Chemoradiotherapy for Unresectable Stage III Non-Small Cell Lung Cancer Clin. Cancer Res., July 1, 2005; 11(13): 5045s - 5050s. [Abstract] [Full Text] [PDF]

				H. J. M. Groen, A. H. W. van der Leest, E. Fokkema, P. R. Timmer, G. D. Nossent, W. J. G. M. Smit, J. Nabers, H. J. Hoekstra, J. Hermans, R. Otter, et al. Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study Ann. Onc., March 1, 2004; 15(3): 427 - 432. [Abstract] [Full Text] [PDF]